Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
125
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

3.5K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
3.5K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

157
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
157

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Post-Artemisinin anti-malarial discovery from nature: unaltered natural products, lead optimisation, and advanced techniques in the discovery.

Natural product research·2026
Same author

Palladium(II)-catalysed intramolecular hydroamination of 3-alkynyltetrahydroquinolines to methanobenzo[<i>b</i>]azepines.

Chemical communications (Cambridge, England)·2025
Same author

Cascade Reactions of Indigo with an Allenylic Reactant.

Molecules (Basel, Switzerland)·2025
Same author

Beyond absorption: online photoreactor mass spectrometry assessment of new acylphosphine oxide photoinitiators.

Chemical science·2025
Same author

Metabolomic Approach in Anticancer Biomarker Discovery from Foliose Lichens.

Advanced pharmaceutical bulletin·2025
Same author

Mapping of Some Further Alkylation-Initiated Pathways to Polyheterocyclic Compounds from Indigo and Indirubin.

Molecules (Basel, Switzerland)·2024

相关实验视频

Updated: Jun 22, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

目前和正在进行的发展在准困难菌感染和复发.

Wendy Y Cun1, Paul A Keller1, Stephen G Pyne1

  • 1School of Chemistry and Molecular Science, Molecular Horizons Institute, University of Wollongong, Wollongong, NSW 2522, Australia.

Microorganisms
|June 27, 2024
PubMed
概括

困难杆菌感染会导致严重的胃肠道问题. 本综述涵盖了感染原因,风险和新兴的治疗方法,如小分子,便微生物群移植和疫苗.

科学领域:

  • 微生物学 微生物学
  • 传染性疾病 传染性疾病
  • 胃肠病学 胃肠病学

背景情况:

  • 困难菌 Clostridioides 是一种 Gram 阳性,子形成的无氧细菌,负责人类显著的胃肠道感染.
  • 了解C. difficile感染 (CDI) 病原体,毒性和风险因素对于有效管理至关重要.
  • 疾病复发和当前的治疗局限性需要探索新的治疗策略.

研究的目的:

  • 为了提供关于Clostridioides difficile感染 (CDI) 的全面概述.
  • 审查与CDI相关的致病,毒性,风险因素和复发问题.
  • 讨论CDI治疗的最新进展.

主要方法:

  • 对Clostridioides difficile.现有研究的文献综述.
  • 对CDI的致病性,毒性和临床方面的分析.
  • 编译和分类现有和新兴的治疗策略.

主要成果:

  • 由于病变和复发,C. difficile感染带来了重大挑战.
  • 一系列新的治疗方法正在研究中.
  • 这些包括针对毒素形成的小分子,细胞膜和分泌,以及免疫系统的激活.
关键词:
克洛斯特里迪奥伊德困难感染.阴阳性皮多米米特学它们是胺素 (cephamycins).膜的破坏破坏.球体的分泌和分泌.治疗药物 治疗药物毒性因素是毒性的因素.这是一种β-lactam.

更多相关视频

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.7K

相关实验视频

Last Updated: Jun 22, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.7K

结论:

  • 新兴的疗法在对抗C. difficile感染方面表现有前途.
  • 讨论的治疗方法包括便微生物群治疗,基于抗体的免疫疗法,益生菌,疫苗和紫蓝光消毒.
  • 进一步的研究和临床试验对于验证这些新的CDI管理方法至关重要.